The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1
Sign Up to like & getrecommendations! Published in 2018 at "OncoImmunology"
DOI: 10.1080/2162402x.2018.1434468
Abstract: ABSTRACT Cancer immunotherapists have been searching for biomarkers predicting patient responses to PD-1/PD-L1 blockade in neoplastic cells as well as in the immune system. Now, accumulating evidence indicates that the composition of the intestinal microflora… read more here.
Keywords: immune checkpoint; microbiota determines; clinical efficacy; intestinal microbiota ... See more keywords